Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.

Abstract: Mechanisms, in a system comprising a host system and at least one accelerator device, for performing a concept analysis operation are provided. The host system extracts a set of one or more concepts from an information source and provides the set of one or more concepts to the accelerator device. The host system also provides at least one matrix representation data structure representing a graph of concepts and relationships between concepts in a corpus. The accelerator device executes the concept analysis operation internal to the accelerator device to generate an output vector identifying concepts in the corpus, identified in the at least one matrix representation data structure, related to the set of one or more concepts extracted from the information source. The accelerator device outputs the output vector to the host system which utilizes the output vector to respond to a request submitted to the host system associated with the information source.

Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: A method for creating a stable protein/antibody ionic liquid, comprising: (a) cationizing aqueous proteins/antibodies by addition of an excess of a positively-charged crosslinker in the presence of a coupling reagent; (b) purifying the cationized proteins/antibodies; (c) titrating the cationized proteins/antibodies with a corresponding biologically-compatible counter anionic polymer to create at least one protein/antibody cation/anion pair in aqueous solution until the cation/anion pair solution becomes negative by zeta potential measurement; (d) repeatedly dialyzing the protein/antibody cation/anion pair in water to remove excess anionic polymer using at least one molecular weight cutoff 7000 dialysis membrane; (e) lyophilizing the protein/antibody cation/anion pair to remove most of the water, forming a lyophilized solid; and (f) heating the lyophilized solid until a protein/antibody ionic liquid is generated. The antibody may be any desired antibody, and the anion may be any biologically-compatible anion.

Abstract: An industrial control I/O module for interfacing with industrial control equipment, such as sensors and actuators, can be configured to dynamically provide differing resistances in each channel as may be required for reliably achieving particular modes of operation in the channel. Providing differing resistances in such channels flexibly allows different modes in the channel to provide universal I/O capability. Modes of operation could include, for example, digital output, digital input, analog output, analog input and the like, in the same channel, but at different times. In one aspect, a processor or voltage divider can be used to control an amplifier, with feedback, driving a transistor in a channel to dynamically adjust resistance in the channel by selectively biasing the transistor to achieve a resistance in the channel suitable for the selected mode.

Abstract: The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.

Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: A plurality of memory maps may be allocated that represents the hash table on a memory device to store keys and values. The memory maps may comprise at least a primary map and a secondary map. A hash table operation may be performed on the primary map based on a first position computed using a first hash function, and if not successful, a bounded linear probing that probes a defined primary probe region in the primary map. Responsive to determining that the hash table operation on the primary map is not successful, the hash table operation may be performed on the secondary map based on a second position computed using a second hash function, and if not successful, a bounded linear probing that probes a defined secondary probe region in the secondary map.

Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

Abstract: A method, apparatus, and computer program product are provided for generating a set of token sequences for at least a portion of a database, wherein each token in a sequence represents a respective database entity of the database; assigning, for each token in the set of token sequences, at least one corresponding vector from a set of vectors of a same dimension, wherein the at least one corresponding vector encodes relationships between the database entity of a token and other database entities of other tokens of the set of token sequences; and extracting, using a query language, information from the database based at least in part on the relationships encoded by the assigned vectors.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: A plurality of memory maps may be allocated that represents the hash table on a memory device to store keys and values. The memory maps may comprise at least a primary map and a secondary map. A hash table operation may be performed on the primary map based on a first position computed using a first hash function, and if not successful, a bounded linear probing that probes a defined primary probe region in the primary map. Responsive to determining that the hash table operation on the primary map is not successful, the hash table operation may be performed on the secondary map based on a second position computed using a second hash function, and if not successful, a bounded linear probing that probes a defined secondary probe region in the secondary map.

Abstract: Mechanisms, in a system comprising a host system and at least one accelerator device, for performing a concept analysis operation are provided. The host system extracts a set of one or more concepts from an information source and provides the set of one or more concepts to the accelerator device. The host system also provides at least one matrix representation data structure representing a graph of concepts and relationships between concepts in a corpus. The accelerator device executes the concept analysis operation internal to the accelerator device to generate an output vector identifying concepts in the corpus, identified in the at least one matrix representation data structure, related to the set of one or more concepts extracted from the information source. The accelerator device outputs the output vector to the host system which utilizes the output vector to respond to a request submitted to the host system associated with the information source.

Abstract: The present invention relates to the use of in vivo contrast agents in medical imaging in order to diagnose and treat disease, and to monitor and assess disease progression following treatment with a nanoparticle therapeutic agent comprising an active pharmaceutical agent. The present invention also relates to modulating nanoparticle tumor concentration by modulating the PEG density of the nanoparticles.

Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.